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Abstract 
Aims: Interleukin‑22 (IL‑22) has beneficial effects on body weight, insulin resistance and inflammation in different 
mouse models, but its relevance for the development of type 2 diabetes in humans is unknown. We aimed to identify 
correlates of serum IL‑22 levels and to test the hypothesis that higher IL‑22 levels are associated with lower diabetes 
incidence.
Methods: Cross‑sectional associations between serum IL‑22, cardiometabolic risk factors and glucose tolerance sta‑
tus were investigated in 1107 persons of the population‑based KORA F4 study. The prospective association between 
serum IL‑22 and incident type 2 diabetes was assessed in 504 initially non‑diabetic study participants in both the 
KORA F4 study and its 7‑year follow‑up examination KORA FF4, 76 of whom developed diabetes.
Results: Male sex, current smoking, lower HDL cholesterol, lower estimated glomerular filtration rate and higher 
serum interleukin‑1 receptor antagonist were associated with higher IL‑22 levels after adjustment for confounders (all 
P < 0.05). Serum IL‑22 showed no associations with glucose tolerance status, prediabetes or type 2 diabetes. Baseline 
serum IL‑22 levels (median, 25th/75th percentiles) for incident type 2 diabetes cases and non‑cases were 6.28 (1.95; 
12.35) and 6.45 (1.95; 11.80) pg/ml, respectively (age and sex‑adjusted P = 0.744). The age and sex‑adjusted OR (95% 
CI) per doubling of IL‑22 for incident type 2 diabetes of 1.02 (0.85; 1.23) was almost unchanged after consideration of 
further confounders.
Conclusions: High serum levels of IL‑22 were positively rather than inversely associated with several cardiometabolic 
risk factors. However, these associations did not translate into an increased risk for type 2 diabetes. Thus, our data 
argue against the utility of IL‑22 as biomarker for prevalent or incident type 2 diabetes in humans, but identify poten‑
tial determinants of IL‑22 levels which merits further research in the context of cardiovascular diseases.
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Background
Interleukin-22 (IL-22), a member of the IL-10 cytokine 
family, is produced by different leukocyte subsets and 
signals through a heterodimer of the IL-22 receptor 1 
(IL-22R1) paired with IL-10R2. While the latter is widely 
expressed, expression of IL-22R1 is restricted mainly 
to cell types in the pancreas and epithelial cells in liver, 
intestine, kidney and skin, which determines the specific-
ity of IL-22 action [1, 2].
IL-22 represents a crucial regulator of gut epithelial 
barrier integrity and thereby prevents peripheral dis-
semination of commensal bacteria and limits systemic 
inflammation [3]. A recent study extended these data to 
metabolic disorders and found that mice lacking IL-22 
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signaling are prone to obesity and insulin resistance [4]. 
Several mouse models of obesity also revealed beneficial 
effects of IL-22 treatment on glucose homeostasis, insu-
lin sensitivity, insulin secretion and inflammation [4, 5]. 
Other studies have challenged the notion that IL-22 ame-
liorates insulin resistance and chronic inflammation in 
mice [6] or humans [7, 8].
To date, it remains unclear how IL-22 is regulated in 
humans, which physiological role circulating IL-22 levels 
exert and whether endogenous IL-22 levels are associated 
with protection against obesity and related disorders. 
Two cross-sectional studies reported higher rather than 
lower systemic levels of IL-22 in patients with type 2 dia-
betes and in patients with coronary artery disease from 
hospital-based samples than in healthy controls [9, 10], 
but population-based data or prospective studies on 
IL-22 and cardiometabolic diseases are not available.
Therefore, the aims of this study were (1) to identify 
correlates of IL-22 serum levels within a population-
based cohort and (2) to test the hypothesis (based on the 
aforementioned mechanistic studies) that higher serum 




Data are based on the Cooperative Health Research in 
the Region of Augsburg (KORA) F4 study (2006–2008) 
and the KORA FF4 study (2013–2014), both follow-up 
examinations of the population-based KORA S4 study 
(1999–2001) conducted in Augsburg (Germany) and two 
surrounding counties. The design of the KORA studies 
has been described before [11].
All study participants without known diabetes were 
assigned to receive a standard 75-g oral glucose tolerance 
test (OGTT) in both KORA F4 and KORA FF4. Glucose 
tolerance categories were defined using fasting and 2-h 
glucose levels according to the 2003 American Diabetes 
Association criteria [12]. Prediabetes was defined as IFG, 
IGT or combined IFG/IGT. Previously known type 2 dia-
betes was defined as self-report that could be validated 
by the responsible physician, or as current use of antidia-
betic agents. Incident type 2 diabetes in KORA FF4 was 
defined based on a self-reported diagnosis of type 2 dia-
betes since KORA F4 that could be validated, current use 
of antidiabetic agents, or fasting and/or 2-h glucose levels 
in the OGTT above the aforementioned criteria.
This study included all persons aged 62–81  years in 
KORA F4 (n = 1161). For the cross-sectional study part 
we excluded persons with unclear glucose tolerance 
status due to missing values for fasting and/or 2-h glu-
cose (n =  26), type 1 diabetes (n =  2) or other missing 
covariables (n =  26), resulting in a sample size of 1107 
individuals.
The prospective part used all of these participants, 
for whom follow-up data from KORA FF4 were avail-
able (n = 641). Baseline characteristics of the drop-outs 
from the cross-sectional analysis sample (n  =  1107) 
who did not participate in KORA FF4 (n  =  466) are 
summarised in Additional file  1: Table S1. Reasons for 
non-participation included the following: individu-
als had died, refused/were too ill/were not interested 
or too busy to participate, or could not be contacted. 
Since incident type 2 diabetes was studied as outcome 
we excluded participants with known (n = 76) or newly 
diagnosed (n =  39) type 2 diabetes in KORA F4, with 
unclear glucose tolerance status due to missing values 
for fasting and/or 2-h glucose (n  =  21) or with other 
missing covariables (n = 1), which left a sample size of 
504 individuals.
The assessment of anthropometric and metabolic vari-
ables and of lifestyle factors was performed as described 
[11, 13]. Hypertension was defined as blood pressure of 
140/90 mmHg or higher, or antihypertensive medication 
given that the subjects were aware of being hypertensive. 
The estimated glomerular filtration rate (eGFR) was cal-
culated using the chronic kidney disease epidemiology 
(CKD-EPI) creatinine equation [14]. Study participants 
were classified as physically active if they reported >1 h 
sports/week in summer and in winter.
Quantification of IL‑22 serum levels
IL-22 levels were assessed in serum samples that had 
been continuously stored at −80  °C between blood 
sampling and analysis, which was performed between 
08/2015 and 10/2015. Measurements were carried out 
using the Quantikine ELISA (R&D Systems, Wiesbaden, 
Germany). The limit of detection (LOD) was 3.9  pg/
ml. Measurements below the LOD for 347 sera were 
assumed to be evenly distributed between 0 and the LOD 
and therefore assigned a value of 0.5*LOD as in previous 
analyses within the KORA cohort [15, 16]. Values > 99th 
percentile (extreme outliers between 74.4 and 406 pg/ml, 
n = 11) were assigned the IL-22 level of the 99th percen-
tile (74.4 pg/ml). Intra- and inter-assay CV were 5.5 and 
9.3%, respectively.
Statistical analysis
Associations between serum IL-22 and other variables of 
the KORA F4 sample were described by baseline char-
acteristics stratified by quarters of IL-22 levels and age 
and sex-adjusted P values from linear regression analysis. 
Due to the high number of samples with IL-22 below the 
LOD, quarter sizes were unequal with quarter 1 (com-
prising all individuals with IL-22 below the LOD) being 
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larger than quarters 2–4 (comprising all individuals with 
measurable IL-22 levels).
Independent correlates of IL-22 levels at baseline 
were identified by multivariable linear regression anal-
ysis employing a forward selection of variables and 
exclusion of variables without significant association 
(P > 0.05) with serum ln (IL-22). We added the follow-
ing covariables: step 1, age and sex; step 2, smoking 
status (current/former/never), alcohol consumption, 
physical activity (active/inactive); step 3, BMI; step 4, 
HDL cholesterol, LDL cholesterol, triglycerides, hyper-
tension (yes/no), history of myocardial infarction (yes/
no), eGFR; step 5, circulating levels of high-sensitivity 
C-reactive protein (hsCRP), IL-6, IL-18, tumour necro-
sis factor (TNF)α, IL-1 receptor antagonist (IL-1RA), 
soluble intercellular adhesion molecule-1 (sICAM-1), 
adiponectin.
Cross-sectional associations of ln(IL-22) with single 
glucose tolerance status groups or with prediabetes/dia-
betes were estimated by multinomial logistic regression 
with normal glucose tolerance as reference and using the 
following predefined set of potential confounders from 
previous KORA analyses [11]: model 1, adjusted for age 
and sex; model 2, model 1 + smoking, alcohol consump-
tion, physical activity; model 3, model 2 +  BMI; model 
4, model 3 + HDL cholesterol, LDL cholesterol, triglyc-
erides, hypertension, prevalent myocardial infarction, 
eGFR. Age, alcohol consumption, BMI, HDL cholesterol, 
LDL cholesterol, triglycerides and eGFR entered the 
models as continuous variables.
The association between a doubling in serum IL-22 
as continuous variable and incident type 2 diabetes in 
the prospective analysis was assessed by multivariable 
logistic regression using the same set of covariables as in 
the cross-sectional analysis. We performed a test of lin-
earity in IL-22 using restricted cubic splines functions 
with k =  3, 4, 5 equally spaced knots between the 0.05 
and 0.95 quantiles for the fully adjusted model 4 using 
the ‘rms’ package in R. Potential sex differences were 
assessed using an interaction term IL-22*sex in the logis-
tic regression models.
We performed the following sensitivity analyses: (1) 
analysis of the original dataset before replacement of out-
liers with IL-22 levels corresponding to the 99th percen-
tile; (2) analysis of the data treating IL-22 as dichotomous 
exposure (IL-22 levels above versus below the LOD); (3) 
analysis restricted to current non-smokers.
All statistical analyses were performed with R version 
3.2.4 (R Core Team, R Foundation for Statistical Comput-
ing, Vienna, Austria). A P value <0.05 was considered to 
indicate statistical significance.
Results
Associations of serum IL‑22 levels with cardiometabolic 
risk factors
In the cross-sectional analysis based on 1107 individuals, 
IL-22 serum levels were higher in men than in women 
(distributions shown in Additional file 1: Figure S1) and 
positively associated with age (Table 1). In age and sex-
adjusted analyses, IL-22 serum levels were positively 
associated with BMI, fasting and 2-h insulin, HOMA-
IR, smoking status and circulating levels of IL-18, IL-
1RA and sICAM-1, but negatively with total cholesterol, 
HDL cholesterol and estimated glomerular filtration rate 
(eGFR) (Table 1).
Multivariable linear regression analysis identified male 
sex, current smoking, lower HDL cholesterol, lower 
eGFR and higher serum IL-1RA as independent corre-
lates of higher IL-22 (Table 2).
However, serum IL-22 did neither differ between 
groups with different glucose tolerance status (Addi-
tional file 1: Table S2) nor between individuals with nor-
mal glucose tolerance, prediabetes (IFG and/or IGT) or 
type 2 diabetes (Additional file 1: Table S3) at all levels of 
adjustment.
No association between serum IL‑22 levels and incident 
type 2 diabetes
As shown in Additional file 1: Table S1, individuals with-
out follow-up data (i.e. non-participants in KORA FF4) 
were older, had a higher BMI and a less favourable car-
diometabolic risk profile compared to individuals who 
participated in KORA FF4. Importantly, serum IL-22 did 
not differ between both groups.
The prospective part of the study was based on 504 
individuals who were free of diabetes in the KORA F4 
survey and for whom all relevant data from the follow-up 
KORA FF4 study were available.
Of these, 76 individuals developed type 2 diabetes, 
whereas 428 individuals remained diabetes-free. Baseline 
levels of serum IL-22 levels (median and 25th/75th per-
centiles) were 6.45 (1.95; 11.80) pg/ml for cases and 6.28 
(1.95; 12.35) pg/ml for non-cases (age and sex-adjusted 
P  =  0.744, Additional file  1: Table S4), which was 
reflected by an OR (95% CI) per doubling of serum IL-22 
(i.e. twofold increase in baseline IL-22) for incident type 
2 diabetes of 1.02 (0.85; 1.23) (Table 3). Addition of fur-
ther covariables to the model had virtually no impact on 
the results (Table 3). We did not detect any indication for 
non-linearity (Wald statistics: P = 0.524 for k = 3 knots, 
P = 0.549 for k = 4 knots, P = 0.714 for k = 5 knots for 
the fully adjusted model 4). We did not observe a sig-
nificant interaction by sex for this association (Pinteraction 
between 0.07 and 0.14 for models 1–4).
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Table 1 Description of the KORA F4 study population stratified by quarters of IL-22 concentrations (cross-sectional anal-
ysis)
Data are given as mean ± SD, median and 25th; 75th percentiles or percentages, unless indicated otherwise. The age and sex-adjusted P values are from linear 
regression analysis (likelihood ratio tests comparing models with ln IL-22 as dependent variable and the respective variable, age and sex as independent variables to 
models with age and sex as independent variables only). The analysis for age is adjusted for sex only, the analysis for sex is adjusted for age only
eGFR, estimated glomerular filtration rate; hs, high-sensitivity; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; ISI, insulin sensitivity index; ndT2D, newly 
diagnosed type 2 diabetes; NGT, normal glucose tolerance; T2D, type 2 diabetes
a Adjusted for age and sex
b Individuals with known type 2 diabetes excluded (n = 160)
c Individuals using lipid-lowering drugs excluded (n = 270)
Variable Quarter 1 Quarter 2 Quarter 3 Quarter 4 Pa
n 347 208 277 275
IL‑22 (pg/ml; range) 1.95–1.95 3.90–6.74 6.78–13.33 13.36–74.39
Age (years) 69.6 ± 5.3 70.2 ± 5.5 70.3 ± 5.1 70.9 ± 5.7 0.002
Sex (% male) 31.7 48.6 57.4 73.1 <0.001
BMI (kg/m2) 28.2 ± 4.6 28.7 ± 4.5 29.5 ± 4.1 28.7 ± 4.5 0.007
Fasting glucose (mmol/l)b 5.45 ± 0.85 5.49 ± 0.62 5.56 ± 0.65 5.50 ± 0.62 0.483
2‑h glucose (mmol/l)b 7.05 ± 2.28 7.13 ± 2.25 7.31 ± 2.39 7.04 ± 2.29 0.697
Fasting insulin (pmol/l)b 29.1 (19.8; 45.8) 27.0 (19.8; 43.5) 31.8 (21.0; 64.5) 31.5 (21.0; 57.6) <0.001
2‑h insulin (pmol/l)b 307.8 (175.8; 474.0) 319.8 (156.0; 506.2) 372.6 (219.0; 597.6) 321.3 (192.3; 583.4) 0.004
HOMA‑IRb 1.17 (0.75; 1.92) 1.11 (0.79; 1.80) 1.31 (0.81; 2.71) 1.24 (0.80; 2.49) <0.001
ISI (composite) (1/
((mmol/l)x(pmol/l)))b
18.0 (10.4; 27.5) 17.7 (10.4; 32.4) 14.4 (8.6; 24.5) 16.5 (9.0; 27.4) 0.869
HbA1c (%) 5.61 ± 0.47 5.60 ± 0.35 5.65 ± 0.34 5.63 ± 0.38 0.419
HbA1c (mmol/mol) 38 ± 5 38 ± 4 38 ± 4 38 ± 4 0.419
Glucose tolerance status: 
NGT/IFG/IGT/IFG&IGT/
ndT2D/T2D (%)
43.8/16.1/12.1/11.5/5.2/11.2 41.3/19.2/8.7/11.1/7.7/12.0 34.7/22.0/8.7/9.7/7.9/17.0 36.7/18.5/9.1/12.0/5.8/17.8 0.766
Hypertension (%) 59.4 56.5 67.0 67.0 0.628
Total cholesterol (mmol/l)c 6.13 ± 1.05 5.95 ± 0.99 5.84 ± 0.99 5.69 ± 0.96 0.002
LDL cholesterol (mmol/l)c 3.88 ± 0.95 3.84 ± 0.86 3.81 ± 0.88 3.63 ± 0.88 0.072
HDL cholesterol (mmol/l)c 1.56 ± 0.38 1.48 ± 0.34 1.37 ± 0.35 1.35 ± 0.36 <0.001
Triglycerides (mmol/l)c 1.26 (0.91; 1.74) 1.22 (0.92; 1.64) 1.31 (1.01; 1.85) 1.30 (0.91; 1.84) 0.635
Use of lipid‑lowering 
drugs (%)
24.2 23.2 26.4 23.8 0.865
eGFR (ml/min per 1.73 m2) 79.7 ± 12.8 77.3 ± 13.8 74.9 ± 14.8 73.3 ± 17.7 <0.001
eGFR < 60 ml/min per 
1.73 m2) (%)
6.9 13.9 16.6 21.8 <0.001
Smoking (never/former/
current) (%)
61.4/35.4/3.2 53.8/38.0/8.2 47.5/44.2/8.3 38.6/49.3/12.1 <0.001
Physically active (%) 53.6 51.4 49.6 44.5 0.174
hs C‑reactive protein 
(mg/l)
1.44 (0.70; 2.87) 1.38 (0.72; 2.91) 1.59 (0.87; 3.21) 1.94 (0.89; 3.90) 0.310
IL‑6 (pg/ml) 1.43 (0.93; 2.28) 1.52 (1.03; 2.12) 1.70 (1.27; 2.51) 1.92 (1.33; 2.92) 0.586
IL‑18 (pg/ml) 296.0 (228.0; 379.0) 308.0 (251.5; 412.0) 344.5 (269.2; 433.8) 342.5 (263.8; 451.2) 0.032
Tumour necrosis factor α 
(pg/ml)
1.91 (1.40; 2.77) 1.84 (1.38; 2.42) 2.18 (1.61; 3.17) 2.22 (1.63; 3.16) 0.305
IL‑1 receptor antagonist 
(pg/ml)
295.7 (224.1; 393.3) 289.1 (235.0; 384.1) 326.2 (247.3; 432.2) 323.1 (248.4; 446.1) <0.001
Soluble intercellular adhe‑
sion molecule 1 (ng/ml)
228.4 ± 53.9 235.9 ± 49.9 241.8 ± 58.0 246.1 ± 67.7 <0.001
Adiponectin (µg/ml) 11.62 (8.13; 17.25) 9.87 (6.79; 14.82) 8.82 (5.68; 13.8) 9.30 (5.94; 12.88) 0.311
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Our sensitivity analyses showed almost identical results 
(1) when we used the original dataset before replacement 
of outliers with IL-22 levels corresponding to the 99th 
percentile; (2) when we treated IL-22 as dichotomous 
exposure (IL-22 levels above versus below the LOD) 
and (3) when we restricted our analysis to non-smokers 
(Additional file 1: Table S5).
Discussion
The main findings of this study are that (1) serum IL-22 
exhibited positive rather than negative associations with 
multiple cardiometabolic risk factors of type 2 diabetes 
and related complications and (2) IL-22 levels were nei-
ther associated with glucose tolerance and diabetes status 
nor with incident type 2 diabetes during a 7-year follow-
up period.
IL‑22 and cardiometabolic risk factors
Our data are novel because previous studies on IL-22 and 
metabolic disorders mainly focused on mouse models, 
whereas research in humans is warranted to assess the 
potential role of IL-22 as biomarker for diabetes risk or as 
candidate for treatment studies [17]. This study extends 
the current literature by demonstrating that male sex, 
current smoking, lower HDL cholesterol, lower eGFR 
and higher IL-1RA were associated with higher IL-22 lev-
els independently of confounders.
It can be speculated that sex hormones are regulators of 
IL-22, but data from experimental or other epidemiologi-
cal studies in this context are not available. The positive 
association between current smoking and higher IL-22 
levels is in line with proinflammatory effects of smoking 
that have been demonstrated in mechanistic studies and 
that are reflected by a systemic upregulation of numerous 
other biomarkers of inflammation [18]. Due to the cross-
sectional design of the study the causal directions in the 
associations between higher IL-22 on the one hand and 
lower HDL cholesterol, lower eGFR and higher IL-1RA on 
the other hand cannot be determined. However, there is 
evidence from other experimental settings that may be rel-
evant for a better understanding of our observations. First, 
IL-22 has been demonstrated to downregulate the expres-
sion of ATP-binding cassette sub-family G member 1 
(ABCG1) and to reduce cholesterol efflux in macrophages, 
which may link IL-22 with decreased HDL cholesterol lev-
els and increased cardiovascular risk [19]. Second, IL-22 
has been reported to have both beneficial and detrimen-
tal effects depending on the type of experimental model of 
kidney injury [2, 20]. Data from other human cohorts are 
not available, so that further studies are necessary to con-
firm the inverse association between IL-22 and eGFR and 
to explore the relevance of this association for the devel-
opment of chronic kidney disease in older individuals. 
Third, IL-22 has been implicated in the increased produc-
tion of IL-1RA mediated by protein kinase C δ (PKCδ) and 
NLR family CARD domain-containing protein 4 (NLRC4) 
[21], which suggests that IL-22 could indeed contribute to 
higher IL-1RA levels. An alternative explanation is related 
to the fact that the proinflammatory cytokine IL-1β is not 
only a known positive regulator of its endogenous inhibi-
tor IL-1RA, but also of IL-22 [1, 2, 7], so that the associa-
tion found in our cohort could as well reflect the result of 
a joint upregulation of both proteins downstream of IL-1β.
In addition, we found positive associations with age, 
BMI, fasting and 2-h insulin, HOMA-IR, IL-18 and 
sICAM-1. These were, however, not significant after 
extensive adjustment, but may also link higher IL-22 lev-
els with higher risk of cardiometabolic diseases.
We observed that the dynamic range of IL-22 in the cir-
culation appears to span at least two orders of magnitude 
Table 2 Correlates of  IL-22 levels at  baseline (cross-sec-
tional analysis): final model from  multivariable linear 
regression analysis
Regression coefficients β and corresponding 95% confidence intervals (per 
given unit in the table) and P values are based on a final model with ln(IL-22) as 
dependent variable after a forward selection including blocks of independent 
variables at each step (see below). At each step non-significant variables 
(P > 0.05) were excluded from further analysis
Step 1 age and sex
Step 2 smoking status, alcohol consumption, physical activity
Step 3 BMI
Step 4 HDL cholesterol, LDL cholesterol, triglycerides, hypertension, history of 
myocardial infarction, eGFR
Step 5 hsCRP, IL-6, IL-18, TNFα, IL-1RA, sICAM-1, adiponectin
eGFR, estimated glomerular filtration rate; IL-1RA, IL-1 receptor antagonist
Variable β (95% CI) P
Male sex 0.524 (0.401; 0.648) <0.001
Current smoking 0.439 (0.228; 0.651) <0.001
Former smoking 0.060 (−0.061; 0.181) 0.332
HDL cholesterol (mmol/l) −0.172 (−0.337; −0.008) 0.041
eGFR (ml/min per 1.73 m2) −0.010 (−0.014; −0.007) <0.001
IL‑1RA (pg/ml) 0.001 (0.000; 0.001) <0.001
Table 3 OR (95% CI) for incident type 2 diabetes per dou-
bling in serum IL-22 (prospective analysis)
Model Covariables OR (95% CI) P
1 Age, sex 1.02 (0.84; 1.23) 0.838
2 Model 1 + current smoking, former 
smoking, alcohol consumption, 
physical activity
1.04 (0.86; 1.26) 0.703
3 Model 2 + BMI 1.01 (0.83; 1.24) 0.893
4 Model 3 + HDL cholesterol, LDL 
cholesterol, triglycerides, use of lipid‑
lowering drugs, hypertension, preva‑
lent myocardial infarction, estimated 
glomerular filtration rate
1.03 (0.83; 1.27) 0.797
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in the general population with a large proportion of indi-
viduals showing very low levels (i.e. below our LOD of 
3.9 pg/ml). This could indicate that IL-22 levels are tightly 
regulated in the absence of appropriate stimuli. However, 
the demographic, anthropometric and metabolic charac-
teristics of this subgroup did not differ very strongly from 
the remainder of the cohort, so that the precise reason 
for the broad distribution of circulating IL-22 needs fur-
ther research.
Taken together, our study provides novel data on the 
relationships between IL-22 levels and sex, smoking, lipid 
metabolism, IL-1β-related processes and kidney function 
that merit further studies. Importantly, the data suggest 
that higher endogenous circulating IL-22 may be related 
to higher levels of several cardiometabolic risk factors, 
which was not expected given the anti-inflammatory and 
anti-diabetic effects observed in mouse models [3–5].
IL‑22 and type 2 diabetes
Despite the link between higher IL-22 levels and the 
more pronounced cardiometabolic risk profile discussed 
above, it seems that these associations had no detect-
able impact on glucose tolerance and diabetes status. 
Although we observed positive associations of IL-22 with 
fasting and 2-h insulin levels and with HOMA-IR after 
adjustment for age and sex, they were not significant any-
more after further adjustment for confounding factors.
Previous clinical studies found that plasma levels of 
IL-22 and the number of IL-22-producing CD4+ T cells 
were higher in insulin-resistant or type 2 diabetic obese 
individuals than in insulin-sensitive obese or lean indi-
viduals [7, 8], but results were based on very small sam-
ples. In addition, analyses were not adjusted for any 
covariables, which represents an important limitation 
given large differences in HDL cholesterol levels between 
groups in one of the aforementioned studies [7] and 
given our findings that sex, smoking, HDL cholesterol, 
inflammation and kidney function should be considered 
as potential confounders in any analyses of circulating 
IL-22 levels.
In line with these findings, one hospital-based study 
reported higher plasma IL-22 levels in patients with type 
2 diabetes than in healthy controls or individuals with 
metabolically healthy obesity [9]. A second hospital-
based study observed higher serum IL-22 concentrations 
in patients with type 2 diabetes, coronary artery dis-
ease or both conditions compared with healthy controls 
[10]. Although both studies share the limitations that 
patients were older than controls and that comparisons 
between groups were also not adjusted for confounders, 
they are interesting because of the age of the study sam-
ples. Mean ages of the different case and control groups 
were between 42 and 66 years. Thus, the absence of the 
initially hypothesised inverse association between sys-
temic IL-22 levels and type 2 diabetes in our study may 
not be attributable to the advanced age of the KORA F4 
study population.
The aforementioned data were corroborated by mecha-
nistic studies indicating that IL-22 induced insulin resist-
ance in human hepatocytes and rat skeletal muscle cells. 
However, these effects were achieved using in vitro con-
centrations that were  ≥1000-fold higher compared to 
serum levels [7], so that the physiological relevance of 
this observations remains unclear. In contrast, IL-22 was 
also found to protect human endothelial cells from glu-
cose- and lysophosphatidylcholine-induced injury, thus 
supporting atheroprotective effects [10].
Importantly, the associations between IL-22 and 
cardiometabolic risk factors did not translate into an 
increased diabetes risk in the longitudinal part of our 
study. This result may appear unexpected given the stud-
ies in mice indicating diabetes-protective effects. Block-
ing IL-22 signaling resulted in unfavourable effects on 
body weight, glucose tolerance and insulin sensitivity [4], 
whereas treatment with recombinant IL-22 proteins or 
IL-22 overexpression counteracted weight increase and 
improved hyperglycaemia, insulin resistance and inflam-
mation [4, 5, 22]. Incubation of murine and human islets 
with IL-22 (50  ng/ml) reduced oxidative and endoplas-
matic reticulum stress [5]. However, deficiency of endog-
enous IL-22 did not lead to metabolic aberrations [4], and 
one study also failed to observe metabolic consequences 
of IL-22 overexpression [6].
The reason for the discrepancies may lie in the IL-22 
concentrations that were reached in  vivo or applied 
in vitro. IL-22 serum levels in mice were ≤20 pg/ml [6] 
and thus comparable to those in our study. Metabolic 
effects of IL-22 overexpression were observed in trans-
genic lines with circulating IL-22 levels of 4000–7000 pg/
ml [22], but not in a line with serum IL-22 of 600 pg/ml 
[6], thus arguing for protective effects at extremely supra-
physiological levels only [23]. In any case, our data con-
sistently argue against the initially hypothesised inverse 
association between physiological serum levels of IL-22 
and diabetes risk.
One possible interpretation of the divergent findings 
may be that circulating levels of IL-22 represent a bio-
marker for the systemic response against cardiometabolic 
risk factors. Although these factors need to be more pre-
cisely defined, major candidates include not only immu-
nological stimuli, but also oxidative stress, endothelial 
dysfunction, dyslipidemia and further obesity-related 
metabolic disturbances that contribute to the close inter-
relationship between inflammation, type 2 diabetes and 
cardiovascular disease [10, 24–26]. However, such an 
upregulation does not appear to be sufficient to protect 
Page 7 of 8Herder et al. Cardiovasc Diabetol  (2017) 16:17 
against the onset of cardiometabolic diseases, whereas 
higher, experimentally induced concentrations may be 
of therapeutic benefit. This explanation suggests simi-
larities between IL-22 and IL-1RA, which also has diabe-
tes- and atheroprotective effects, but higher circulating 
levels indicate a higher risk of type 2 diabetes and car-
diovascular disease [25, 27, 28]. The fact that one of the 
aforementioned studies found elevated levels of IL-22 in 
groups with type 2 diabetes and coronary artery disease 
compared with healthy controls points into this direction 
[10]. Finally, it remains to be elucidated to what extent 
the interpretation of IL-22 levels as protective or patho-
logical factor depends on the immunological context, i.e. 
on the presence of other cytokines and the overall immu-
nological milieu.
Strengths and limitations
The population-based design and the combination of 
cross-sectional and prospective analyses to identify asso-
ciations of serum IL-22 with cardiometabolic risk factors 
and risk of type 2 diabetes are strengths of this study. Our 
results for incident type 2 diabetes were robust in several 
sensitivity analyses.
The main limitation is the sample size in the prospec-
tive analysis. However, we had a statistical power of 88.9 
and 81.5% to detect an unadjusted OR per doubling of 
serum IL-22 of 0.8 and 1.2, respectively, at α  =  0.05. 
Moreover, we studied older individuals of German 
descent, which limits the generalisability of our observa-
tions to younger populations and populations with non-
European descent. Finally, we were not able to precisely 
quantify serum IL-22 levels in the whole study sample 
because almost one-third of serum samples yielding lev-
els below the LOD of the assay selected for this study.
Conclusion
In the population-based KORA F4 cohort, serum IL-22 
was independently associated with male sex, current 
smoking, lower HDL cholesterol, lower eGFR and higher 
IL-1RA levels, which all represent risk factors of type 2 
diabetes and/or diabetes-related complications. However, 
serum IL-22 was neither independently associated with 
glucose tolerance and diabetes status in a cross-sectional 
setting nor with risk of incident type 2 diabetes dur-
ing a follow-up time of 7  years. Our data argue against 
the utility of IL-22 as specific biomarker for prevalent or 
incident type 2 diabetes in humans, but identify poten-
tial determinants of IL-22 levels which merits further 
research in the context of cardiovascular diseases.
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